FORMULATION AND BIOPHARMACEUTICAL EVALUATION OF SUSTAINED RELEASE PELLETS OF BOSENTAN BY PANCOATING METHOD
DOI:
https://doi.org/10.22159/ijap.2024v16i1.49039Keywords:
Pellets, Pan coating, Eudragit, Bosentan, Independent modelAbstract
Objective: The aim of the present study was to formulate sustained-release pellets of bosentan by eudragit RL 100 and RS 100, which are the polymers used in the pan coating technique.
Methods: The sustained release pellets of bosentan were formulated by pan coating method. The drug was coated on nonpareil seeds along with EudragitRL100 by solution layering technique. Drug-loaded pellets were coated with EudragitRS100. The prepared pellets were evaluated for moisture content, drug content, particle size, and in vitro drug release. Stability studies were carried out on the optimised formulations for a period of 6 mo.
Results: The drug content was in the range of 98.89±0.32. The mean particle size of the drug-loaded pellets was in the range of 835 μm. The drug release rate decreased as the concentration of eudragit increased in the pellet formulations. Among the prepared formulations, PC 4 showed 89.35±0.52 drug release in 12 h from a good linear relationship was established between model-independent approaches (T25%, T50%, and T100%) and weight gain in coating. This indicated the possibility of extending the drug release by increasing the weight gain in the coating, and hence, it was proposed to extend the drug release for 24 h. From the prepared pellets, the optimised formulation PC 12 showed a 100.02±0.03 drug release in 24 h. Furthermore, these pellets were filled into capsules and compared the dissolution studies. The compatibility between drugs and polymers in the drug-loaded pellets was confirmed by DSC and FTIR studies. Stability studies indicated that the pellets were stable.
Conclusion: The prepared pellets were capable of releasing the drug for 24 h to treat the Pulmonary Arterial Hypertension.
Downloads
References
Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527-38. doi: 10.1016/j.jacc.2008.01.024.
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986;29(4):515-24. doi: 10.1002/art.1780290409, PMID 3707629.
Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361(9368):1533-44. doi: 10.1016/S0140-6736(03)13167-4, PMID 12737878.
Galie N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-100. doi: 10.1016/S0140-6736(08)60919-8, PMID 18572079.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. doi: 10.1056/NEJMoa012212, PMID 11907289.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. doi: 10.1016/s0735-1097(02)02012-0, PMID 12204511.
Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999;13(6):1351-6. doi: 10.1183/09031936.99.13613579, PMID 10445611.
MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther. 1998;11(2-3):125-32. doi: 10.1006/pupt.1998.0126, PMID 9918744.
Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995 Dec;79(6):2122-31. doi: 10.1152/jappl.1995.79.6.2122, PMID 8847282.
Varia U, Prajapathi B, Hitesh K. Formulation and development of bosentan loaded once a daily tablet for pulmonary artery hypertension using lipid matrices by 32 full factorial design. IJPSR. 2018;9(11):4729-40. doi: 10.13040/IJPRS.0975-8232.
Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1055-62. doi: 10.1345/aph.1C256, PMID 12841819.
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999 Jul;39(7):703-14. doi: 10.1177/00912709922008344, PMID 10392325.
Robinson JR, Eriksen SP. Theoretical formulation of sustained-release dosage forms. J Pharm Sci. 1966 Nov;55(11):1254-63. doi: 10.1002/jps.2600551118, PMID 5969782.
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996 Aug;60(2):124-37. doi: 10.1016/S0009-9236(96)90127-7, PMID 8823230.
Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999 Jul;27(7):810-5. PMID 10383925.
Tracleer AC. Available from: https://www.accessdata.fda.gov/drugsatfda-docs/label21290seB-001_tracleer_lbl.pdf. [Last accessed on 24 Jun 2017]
VL, Shidhaye S, Kedar U, Kadam V. Formulation and evaluation of novel enteric coated extended release multiparticulates of model NSAID ketoprofen. PCI- Approved-IJPSN. 2010;3(2):994-9. doi: 10.37285/ijpsn.2010.3.2.13.
Indian pharmacopoeia. The controller of publication. 7th ed. New Delhi: Ministry of Family of Health and Family Welfare. India; 2014. p. 258-9.
Venkat NR, Ramarao N, Chandrika K. Design and evaluation of sustained release pellets of aceclofenac. J Pharm Res. 2013 May;6(5):525-31. doi: 10.1016/jopr.2013.04040.
USP. The official compendia of standards. NF25. The United States of America Pharmacopoeial Convention, Powder Flow (e-book); 2007. p. 643-4.
USP. The official compendia of standards. NF25. The United States of America Pharmacopoeial Convention, Bulk Density and Tapped Density (e-book); 2007. p. 242-3.
USP. Powder flow, United States Pharmacopoeial Convention. NF27; 2009. p. 286-7.
Lachman L, Liberman HA, Joseph LK. The Theory and Practice of Industrial Pharmacy. 4th Indian ed. New Delhi: Varghese Publishing House; 2013. p. 27-9.
Roy A, Arees R, Blr M. Formulation development of oral fast-dissolving films of rupatadine fumarate. Asian J Pharm Clin Res. 2020;13:67-72. doi: 10.22159/ajpcr.2020.v13i11.39185.
Kikkinides ES, Charalambopoulou GC, Stubos AK, Kanellopoulos NK, Varelas CG, Steiner CA. A two-phase model for controlled drug release from biphasic polymer hydrogels. J Control Release. 1998 Feb 12;51(2-3):313-25. doi: 10.1016/s0168-3659(97)00182-x, PMID 9685929.
Mulye NV, Turco SJ. A simple model based on first order kinetics to explain release of highly water soluble drugs from porous dicalcium phosphate dihydrate matrices. Drug Dev Ind Pharm. 1995;21(8):943-53. doi: 10.3109/03639049509026658.
Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969 Oct;58(10):1253-57. doi: 10.1002/jps.2600581021, PMID 5349114.
Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963 Dec;52:1145-9. doi: 10.1002/jps.2600521210, PMID 14088963.
Katzhendler I, Hoffman A, Goldberger A, Friedman M. Modeling of drug release from erodible tablets. J Pharm Sci. 1997 Jan;86(1):110-5. doi: 10.1021/js9600538, PMID 9002469.
Korsmeyer RW, Gurny R, Doelker E, Buri P, peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983 May;15(1):25-35. doi: 10.1016/0378-5173(83)90064-9.
Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5(1):37-42. doi: 10.1016/0168-3659(87)90035-6.
International Council on Harmonization, ICH. Stability testing of new drug substances and products available at. p. Q1A (R2). Available from: http://www.ich.org/lOB/media/Q1A R2Guideline.pdf. [Last accessed on 08 May 2017]
Talukdar M. In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. Int J Pharm. 1998;169(1):105-13. doi: 10.1016/S0378-5173(98)00112-4.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27-31. doi: 10.4103/0976-0105.177703, PMID 27057123.
Published
How to Cite
Issue
Section
Copyright (c) 2024 GVRAMI REDDY, PALLAVI V., RAKESH P., RAMARAO NADENDLA
This work is licensed under a Creative Commons Attribution 4.0 International License.
